The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy
Tóm tắt
Clinical outcomes for lymphoma in people living with HIV (PLWH) are similar to those in the general public. However, a number of concerns remain including pharmacological interactions between cytotoxic chemotherapy and antiretroviral therapy (ARVs). Much attention has focussed on pharmacokinetic interactions attributable to effects on hepatic microsomal enzymes, but not on competition for the renal organic anion transport system. High-dose (3 g/m2) intravenous methotrexate (MTX) is part a of (R)-CODOX-M/IVAC chemotherapy regimen for HIV-associated Burkitt/Burkitt-like lymphoma (BL/BLL). We investigated MTX pharmacokinetics and evaluated the effects of renal function (eGFR), age and use of different classes of ARVs. Forty-three PLWH treated with ARVs and (R)-CODOX-M/IVAC are included in the analysis. Plasma MTX concentration was measured (ARK TM MTX assay, VITROS® 5600) daily after administration until levels were <0.04/mmol/L. MTX elimination half-life was correlated with age, renal function and antiretroviral regimen. One hundred and fifty timed plasma MTX levels were collected. The median MTX elimination half-life was 21.7 h (range 9.4–204.4). MTX elimination half-life was not influenced by age (p = 0.71), eGFR (p = 0.67) or use of non-nucleoside reverse transcriptase inhibitors (NNRTIs) or integrase inhibitors (p = 0.15). Similarly, different NRTI backbones did not affect MTX elimination kinetics (p = 0.68), despite the potential overlapping competition for active renal tubular transporters between MTX and tenofovir. Although there is potential competition for active renal tubular transporters between MTX and tenofovir, no prolongation of MTX half-life was observed. These findings are reassuring to clinicians managing patients with dual diagnoses.
Tài liệu tham khảo
Cote TR, Biggar RJ, Rosenberg PS, Devesa SS, Percy C, Yellin FJ, Lemp G, Hardy C, Geodert JJ, Blattner WA (1997) Non-Hodgkin’s lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 73(5):645–650
Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA (2007) AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 99(12):962–972. doi:10.1093/jnci/djm010
Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, Clawson SM, Stenning SP, Yule CL, Jack AS (2008) A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 112(6):2248–2260. doi:10.1182/blood-2008-03-145128
Oriol A, Ribera JM, Bergua J, Gimenez Mesa E, Grande C, Esteve J, Brunet S, Moreno MJ, Escoda L, Hernandez-Rivas JM, Hoelzer D (2008) High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer 113(1):117–125. doi:10.1002/cncr.23522
Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, Hochberg EP, Abramson JS (2011) Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: a retrospective analysis. Ann Oncol 22(8):1859–1864. doi:10.1093/annonc/mdq677
Alwan F, He A, Montoto S, Kassam S, Mee M, Burns F, Edwards S, Wilson A, Tenant-Flowers M, Marcus R, Ardeshna KM, Bower M, Cwynarski K (2015) Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy. AIDS 29(8):903–910. doi:10.1097/QAD.0000000000000623
Bower M, McCall-Peat N, Ryan N, Davies L, Young AM, Gupta S, Nelson M, Gazzard B, Stebbing J (2004) Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 104(9):2943–2946
Griffin L, Annaert P, Brouwer KL (2011) Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J Pharm Sci 100(9):3636–3654. doi:10.1002/jps.22655
Monjanel S, Rigault JP, Cano JP, Carcassonne Y, Favre R (1979) High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach. Cancer Chemother Pharmacol 3(3):189–196
Takeuchi A, Masuda S, Saito H, Doi T, Inui K (2001) Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. Kidney Int 60(3):1058–1068. doi:10.1046/j.1523-1755.2001.0600031058.x
Green MR, Chowdhary S, Lombardi KM, Chalmers LM, Chamberlain M (2006) Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma. Expert Rev Neurother 6(5):635–652. doi:10.1586/14737175.6.5.635
Twelves CJ (1986) Folinic acid rescue and methotrexate toxicity. Lancet 1(8483):737
El-Badawi MG, Abdalla MA, Bahakim HM, Fadel RA (1996) Nephrotoxicity of low-dose methotrexate in guinea pigs: an ultrastructural study. Nephron 73(3):462–466
Zhang W, Zhang Q, Tian X, Zhao H, Lu W, Zhen J, Niu X (2015) Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution. Chin Med J (Engl) 128(1):111–118. doi:10.4103/0366-6999.147829
Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, Moricke A, Stanulla M, Schrappe M, Langer T (2013) Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 121(26):5145–5153. doi:10.1182/blood-2013-01-480335
Jahnke K, Korfel A, Martus P, Weller M, Herrlinger U, Schmittel A, Fischer L, Thiel E (2005) High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 16(3):445–449. doi:10.1093/annonc/mdi075
Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD (2013) Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A: D study. J Infect Dis 207(9):1359–1369. doi:10.1093/infdis/jit043
Kohler JJ, Hosseini SH, Green E, Abuin A, Ludaway T, Russ R, Santoianni R, Lewis W (2011) Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 91(6):852–858. doi:10.1038/labinvest.2011.48